OBA Protocol[removed]MSKCC IRB[removed]Phase I study of In Vitro expanded allogeneic Epstein-Barr Virus specific Cytotoxic T-Lymphocytes (EBV-CTLs) genetically targeted to B cell specific antigen CD 19 positive for In

First Page		Document Content
Date: 2013-12-31 12:39:20 Complement receptor 2 Complement system Epstein–Barr virus Chimeric antigen receptor CD19 Hematopoietic stem cell transplantation Leukemia Anti-CD19 immunotoxin Medicine Anatomy Biology		OBA Protocol[removed]MSKCC IRB[removed]Phase I study of In Vitro expanded allogeneic Epstein-Barr Virus specific Cytotoxic T-Lymphocytes (EBV-CTLs) genetically targeted to B cell specific antigen CD 19 positive for In Add to Reading List Source URL: osp.od.nih.gov Download Document from Source Website File Size: 784,81 KB Share Document on Facebook

	MDACC LEUKEMIA AND LYMPHOMA Europe and the USA Linking Knowledge and Practice DocID: 1vhjk - View Document
	Genome-wide mapping of proviral integration sites in aggresive virus-induced leukemia Nicolas Rosewick1,2, Vincent Hahaut1, Maria Artesi1, Keith Durkin1, Ambroise Marçais3, Philip Griebel4, Natasa Arsic4, Véronique Ave DocID: 1vcJH - View Document
	Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells Lijuan Xia, Duo Chen, Rui Han, et al. Mol Cancer Ther 2005;4:Updated version DocID: 1v6bB - View Document
	The Dual E-selectin/CXCR4 Antagonist GMI-1359 Exerts Anti-leukemia Efficacy Against FLT3-ITDmutated Acute Myeloid Leukemia in A Patient-derived Xenograft Murine Model Mouse-1 Mouse-2 DocID: 1uSbg - View Document
$A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan$	A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan DocID: 1uJQ2 - View Document